Ehrlichia ewingii Polypeptide Diagnostic Assay Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Ehrlichia ewingii infections are inadequate due to the uncultivability of the pathogen and lack of specific serologic tests, leading to difficulties in distinguishing it from other ehrlichiosis agents, especially given shared tick vectors and animal reservoirs, and similar clinical signs.
Innovation Solution
Development of isolated E. ewingii polypeptides and polynucleotides encoding specific proteins, along with a method for detecting antibodies using these polypeptides, to provide a more accurate diagnostic tool for identifying E. ewingii infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If PCR tests based on partial 16S rRNA gene sequence are used, then detection capability is improved, but sensitivity and specificity remain unknown due to lack of comparative tests
Solution Approach 1:
The patent changes the detection parameter from partial 16S rRNA gene sequence to full-length 16S rRNA gene sequence, and introduces additional specific gene targets (groEL, p28) to improve both detection capability and measurement precision through multi-parameter verification
Solution Approach 2:
The patent introduces controlled infection studies using experimentally infected animals as intermediary models to establish gold standard comparative tests, enabling accurate determination of sensitivity and specificity for different diagnostic methods
2Reliability
If Romanovsky dye-staining is used to detect morulae, then definitive proof of ehrlichial infection is obtained, but differentiation between E. ewingii and other granulocytic agents is impossible
Solution Approach 1:
The patent uses species-specific PCR primers and probes as intermediary tools that bridge the gap between general morulae detection and specific E. ewingii identification, enabling both definitive proof and accurate differentiation simultaneously
Solution Approach 2:
The patent applies local quality by designing detection methods that target specific genetic regions unique to E. ewingii (full-length 16S rRNA, groEL, p28 genes) while maintaining the ability to detect general ehrlichial presence through morulae observation
3Ease of operation
If no serologic test is available, then diagnosis remains difficult, but developing specific tests is hindered by uncultivability of the pathogen
Solution Approach 1:
The patent creates genetic copies (PCR amplification) and protein copies (recombinant expression) of E. ewingii targets without requiring live bacterial cultures, enabling serologic test development while respecting the uncultivability constraint
Solution Approach 2:
The patent uses recombinant protein expression systems and synthetic oligonucleotides as intermediaries to produce diagnostic reagents, bypassing the need for pathogen cultivation while enabling serologic test manufacturing
4Loss of time
If clinical signs alone are used for diagnosis, then initial assessment is quick, but distinction between E. ewingii, E. chaffeensis, and A. phagocytophilum cannot be made
Solution Approach 1:
The patent segments the diagnostic process into two stages: rapid initial assessment using clinical signs and basic PCR screening, followed by precise differentiation using species-specific assays, maintaining both speed and accuracy
Solution Approach 2:
The patent develops a multi-functional diagnostic approach where the same laboratory platform can perform both rapid screening for any ehrlichiosis and specific identification of the causative agent, eliminating the trade-off between speed and precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of specific E. ewingii polypeptides and polynucleotides enables effective detection of antibodies, enhancing diagnostic accuracy and differentiation from other ehrlichiosis agents, thereby improving the identification and management of E. ewingii infections.
Implementation Method 1
isolated E. ewingii (EE) polypeptides... Each EE polypeptide has a specific binding affinity for an anti-E. ewingii antibody
Data Source
AI summary
The novel omp-1 gene cluster encoding twenty one Ehrlichia ewingii (EE) proteins was isolated and sequenced completely. This invention relates to isolated E. ewinigii (EE) polypeptides, isolated polynucleotides encoding EE polypeptides, probes, primers, isolated antibodies and methods of their production, immunogenic compositions and vaccines, as well as methods of using the EE polypeptides, antibodies, probes, and primers for the purpose of diagnosis, therapy and production of vaccines against E. ewingii.